Editas Medicine (EDIT) Misses Q4 EPS by 22c

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.55), $0.22 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $30.6 million versus the consensus estimate of $29.59 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Taysha Gene Therapies (TSHA) PT Raised to $10 at BofA Securities
• Trump: everybody is fully aware that Iran will agree to have major weapons inspections in order to ensure "nuclear honesty" long into future